Alnylam Pharmaceuticals ): The pharma company has six commercial products, three of which received a breakthrough designation.

Source: https://investorplace.com/2023/03/3-growth-stocks-that-could-disrupt-the-healthcare-industry/

Amalgamated Bank boosted its stake in Alnylam Pharmaceuticals, Inc. () by 2.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission.

Source: https://www.americanbankingnews.com/2023/06/03/amalgamated-bank-buys-387-shares-of-alnylam-pharmaceuticals-inc-nasdaqalny.html

As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -6.46 EPS for the current year.

Source: https://www.etfdailynews.com/2023/05/28/raymond-james-financial-services-advisors-inc-sells-1200-shares-of-alnylam-pharmaceuticals-inc-nasdaqalny/

Bank of New York Mellon Corp’s holdings in Alnylam Pharmaceuticals were worth $113,517,000 as of its most recent SEC filing.

Source: https://www.etfdailynews.com/2023/03/20/bank-of-new-york-mellon-corp-sells-108017-shares-of-alnylam-pharmaceuticals-inc-nasdaqalny/

Clarius Group LLC acquired a new position in shares of Alnylam Pharmaceuticals, Inc. () in the 3rd quarter, reports.

Source: https://www.etfdailynews.com/2023/01/05/clarius-group-llc-invests-206000-in-alnylam-pharmaceuticals-inc-nasdaqalny/

Finally, 1832 Asset Management L.P. acquired a new position in Alnylam Pharmaceuticals during the 1st quarter worth approximately $88,000.

Source: https://www.dailypolitical.com/2023/10/20/alnylam-pharmaceuticals-inc-nasdaqalny-shares-bought-by-asset-management-one-co-ltd.html

Finally, Canaccord Genuity Group lowered their target price on Alnylam Pharmaceuticals from $310.00 to $291.00 and set a “buy” rating on the stock in a research note on Friday, February 24th.

Source: https://www.etfdailynews.com/2023/05/08/bleakley-financial-group-llc-buys-shares-of-1906-alnylam-pharmaceuticals-inc-nasdaqalny/

Finally, Harvest Fund Management Co. Ltd acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $95,000.

Source: https://www.etfdailynews.com/2023/07/14/alnylam-pharmaceuticals-inc-nasdaqalny-shares-acquired-by-mackenzie-financial-corp/

In related news, CEO sold 7,615 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, April 27th.

Source: https://www.etfdailynews.com/2023/06/04/connor-clark-lunn-investment-management-ltd-invests-295000-in-alnylam-pharmaceuticals-inc-nasdaqalny/

Morgan Stanley cut their target price on Alnylam Pharmaceuticals from $220.00 to $210.00 and set an “equal weight” rating for the company in a research note on Friday, October 28th.

Source: https://www.etfdailynews.com/2023/01/05/clarius-group-llc-invests-206000-in-alnylam-pharmaceuticals-inc-nasdaqalny/

Morgan Stanley decreased their price target on Alnylam Pharmaceuticals from $220.00 to $210.00 and set an “equal weight” rating for the company in a report on Friday, October 28th.

Source: https://www.americanbankingnews.com/2023/01/23/alnylam-pharmaceuticals-inc-nasdaqalny-shares-purchased-by-barclays-plc.html

Needham & Company LLC restated a “buy” rating and issued a $240.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, February 24th.

Source: https://www.etfdailynews.com/2023/05/08/bleakley-financial-group-llc-buys-shares-of-1906-alnylam-pharmaceuticals-inc-nasdaqalny/

Norges Bank purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter worth $240,703,000.

Source: https://www.etfdailynews.com/2023/09/18/alnylam-pharmaceuticals-alny-buy-rating-reaffirmed-at-hc-wainwright/

Oppenheimer dropped their price target on Alnylam Pharmaceuticals from $256.00 to $249.00 and set an “outperform” rating on the stock in a research note on Friday, February 24th.

Source: https://www.etfdailynews.com/2023/06/04/connor-clark-lunn-investment-management-ltd-invests-295000-in-alnylam-pharmaceuticals-inc-nasdaqalny/

Price T Rowe Associates Inc. MD lifted its position in shares of Alnylam Pharmaceuticals by 3.0% in the second quarter.

Source: https://www.etfdailynews.com/2023/03/20/bank-of-new-york-mellon-corp-sells-108017-shares-of-alnylam-pharmaceuticals-inc-nasdaqalny/

The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through sold 4,057 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, August 4th.

Source: https://www.dailypolitical.com/2023/10/20/alnylam-pharmaceuticals-inc-nasdaqalny-shares-bought-by-asset-management-one-co-ltd.html

V Square Quantitative Management LLC acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $53,000.

Source: https://www.etfdailynews.com/2023/10/04/alnylam-pharmaceuticals-nasdaqalny-hits-new-1-year-low-at-168-45/